Oncologo GU, ricercatore, libero pensatore | @iov_irccs | @UniPadova | @unipr | “Nella vita bisognerebbe essere sempre un po' improbabili”Joined December 2023
Updates of STOPCAP? #GU25
STOPCAP shares 7 trials identifying who benefits from ARPi in mHSPC…
✅Benefit of intensification treatment of #mHSPC with ARPi in most patients in OS and PFS
Keep in mind…
📌Young patients have clear benefit from all ARPIs
📌More data needed in…
My dear friend @neerajaiims presenting #TALAPRO2 final OS analysis: TALA + ENZA significantly improved OS vs PBO + ENZA in 1L mCRPC (HR 0.796). rPFS benefit sustained (HR 0.667). Safety consistent with prior reports. Phenomenal! @DrAndreFay#KarimFizazi@ASCO#GU25@OncoAlert
Perioperative durvalumab + neoadjuvant chemo & cystectomy in operable bladder cancer significantly delays (HR 0.68) event free survival and a 25% reduction in the risk of death. 10% ⬆️ pCR. It’s the 1st time immune therapy has an OS benefit in muscle invasive UC #ESM024@NEJM
Neoadjuvant chemotherapy plus durvalumab, followed by adjuvant durvalumab after cystectomy, led to event-free survival superior to that with neoadjuvant chemotherapy followed by cystectomy alone.
Full NIAGARA trial results: nej.md/4gmAqk3#ESMO24
Tivozanib +/- nivolumab in IO pretreated M1 renal cancer showed retreatment with IO makes absolutely no difference. This is on top of CONTACT3 which showed the same thing.We need to stop retreating with IO.These data apply in the post adjuvant setting too without data #ESMO2024
@ciccarese_c rocked the stage presenting preliminary data of TACITO trial investigating #FMT on #mRCC. Primary endpoint 1-y PFS met and no safety issues. Thanks to @gianluca1aniro leading the gastroenterology team & all coinvesigators for this significant achievement.
@OncoAlert
Nectin-4 is the target for Enfortumab Vedotin and is widely expressed in UC (median 275/300) . EV302 is 1st randomised trial to explore its relationship with response. IHC results show no clear relationship between Nectin-4 and outcome (RR,PFS,OS) or PD-L1 #ESMO2024
The 1st disitimab Vedotin (HER-2 MMAE ADC) & pembro showing 1st line response rates of 75% in HER 1-3+ UC. Toxicity profile looks distinct from EV (fatigue>skin). There is a global randomised phase 3 of DV & pembro vs standard chemotherapy. #ESMO24@DrRosenbergMSK @MattGalsky
🚨 Exciting Update! 🚨 Our new EVITA (EV Ineligible criTeriA) criteria for identifying patients ineligible for the EV/Pembro combo in #metastaticurothelialcarcinoma has just been published in @EUplatinum!!!! This breakthrough could significantly reshape daily clinical practice!…
The IBCG Quick Guide to Non-Muscle Invasive Bladder Cancer (NMIBC)
Bladder Cancer Quick Reference Sheet summarizes essential details on diagnosis, treatment options, and follow-up for NMIBC all in one convenient place #AUA24#EAU24#IBCG24#ASCO24
Designed by @AmandaMyersMD…
Enfortumab Vedotin consistently improves PFS and OS compared to chemotherapy, regardless of dose modifications,
⭕️ Dose modifications help manage EV-related side effects without compromising the treatment’s effectiveness.
⭕️Start with 1.25 mg/kg, reduce if needed!
@ASCO#asco24…
40% response rate for chemo +pembro in advanced penile cancer #ASCO24 HPV16-positive (cORR 55.6%) and TMB-high (cORR 75%) potentially enrich. Great investigator initiated study from LACOG and Fernando Maluf

Masterful presentation by #FernandoMaluf presenting results of the #HERCULES LACOG 2018 trial #ASCO24
⚪️ First trial to demonstrate efficacy of ICI in advanced penile cancer w/ manageable safety profile (cORR 42.4% by CR)
⚪️ Pembro + chemo as new Tx option for pts w/ advanced…
The javelin 100 maintenance avelumab trial include ~100 patients who did not have pure UC (such as squamous differentiation). While overall outcome of these patients might be slightly worse avelumab was associated with benifit, supporting its broad use in UC #ASCO24
Biomarker data from KN426 (axi/pembro vs sunitinib) in 1st line RCC. Within arm analysis show T cell signature ⬆️ responses for axi/pembro while angiogenic signatures ⬆️ sunitinib.RNA clusters didn’t define winners. DNA/PD-L1 not helpful. VEGF in both arms is problematic #ASCO24
2K Followers 8K FollowingYour daily source for the latest updates, insights, and news in gastrointestinal oncology. #OncoDailyGI #OncoDaily #GIOncology
261 Followers 361 FollowingUrologist, Sant’Orsola Hospital, FEBU, PhD student, Bologna University, Former Clinical and Research Fellow at OLV Hospital (Aalst) and Orsi Academy (Ghent)
1K Followers 1K FollowingRadiation Oncologist at the European Institute of Oncology Milan; Assistant Professor at the University of Milan Oncology Department Italia 🇮🇹
42 Followers 51 FollowingLuigi Formisano, Patrizia Giannatempo e Roberto Iacovelli ci conducono tra le novità più importanti nel trattamento dei tumori genito-urinari.
130 Followers 760 FollowingWe talk about research, studies, trials, therapies, medical doctors and specialist centers in the world. WE WANT TO GIVE CONCRETE SUPPORT TO PATIENTS
146 Followers 112 FollowingMedical oncologist, PhD in Traslational Oncology
Medical Oncology Unit 2, Molinette Hospital
University Hospital City of Science and Health of Turin, Italy
583 Followers 370 FollowingMedical Oncologist 🇮🇹 Post-Doc in @RolfoLab at The Ohio State University 🇺🇸 Focusing on liquid biopsy and translational research in #LungCancer🩸🧬
4K Followers 258 FollowingSocietà clinico-scientifica degli Oncologi Medici Italiani che conta oltre 2.500 iscritti ed è presieduta dal Prof. Francesco Perrone.
795 Followers 2K FollowingMD, PhD. Medical Oncologist, ASL Caserta. GU and Upper GI tumors. Interested in single cell and spatial transcriptomics applied to cancer
6K Followers 4K FollowingLatest research in oncology | Breaking news, insights, interviews, live tweeting and updates from major conferences | Published by @ilpensiero | @think2it
30 Followers 23 FollowingMedical Oncologist at University Hospital of Parma and Researcher at Department of Medicine and Surgery - University of Parma, Italy
87K Followers 95K FollowingAuthor of the coming book: "The Managed Care Blues: A Doctor's Journey, a Broken System, Real Solutions." Retired physician. Patient and doctor advocate.
419 Followers 302 FollowingGenito-Urinary Medical Oncologist at IRCCS San Raffaele Hospital - PhD Candidate in Molecular Medicine at Vita-Salute San Raffaele University
217 Followers 613 FollowingDr. Waleed Kian is an oncology physician at the Shaare Zedek Medical Center, Jerusalem, Israel.
I have published several papers in the field of lung cancer.
787 Followers 284 FollowingAssociate Profesor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome, Italy. Focused on GU cancers. Husband & father of 2 kids.
3K Followers 2K FollowingChairman of Advanced Radiation Oncology, IRCCS Ospedale S.Cuore Don Calabria, Negrar-Verona & Professor at University of Brescia, Italy 🇮🇹 #radonc
711 Followers 391 FollowingAssociate Professor at @unibo and Medical Oncologist focused on Genitourinary Cancer at IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
6K Followers 4K FollowingLatest research in oncology | Breaking news, insights, interviews, live tweeting and updates from major conferences | Published by @ilpensiero | @think2it
6K Followers 4K FollowingScienziato vagolante, degustatore di Brunello🍷
Andato fieramente in onda a PropagandaLive ❤ Politica, satira, quisquilie. Chi mi ama mi segua. Blocco i fasci!
217 Followers 613 FollowingDr. Waleed Kian is an oncology physician at the Shaare Zedek Medical Center, Jerusalem, Israel.
I have published several papers in the field of lung cancer.
4K Followers 214 FollowingMedical oncologist @harvardmed. Director of Bladder Cancer Program @DanaFarber_GU @IMIMat #bladder #kidney #RCC #prostate #immunotherapy.RTs ≠ endorsment
30K Followers 1K FollowingOfficial account of W. Kimryn Rathmell, MD, PhD (she/her/hers), Director of @theNCI from 12/18/2023. Engagement ≠ endorsement. Privacy: https://t.co/AxsApipSxJ
30K Followers 6K FollowingLargest global online community of #urological medical professionals & patients. #bladdercancer #menshealth #prostatecancer #kidneycancer #Urology
12K Followers 807 FollowingEndowed Professor, Surgeon, Former Fellowship Director @MDAndersonNews | President, IBCG | Assoc Editor @EurUrolOncol | Views my own
29K Followers 698 FollowingMD, PhD, Medical Oncologist | Clinical Fellow @DanaFarber | @Harvard. Associate Editor @ESMO_Open. Interested in breast oncology, HER2, ADCs and good music.
18K Followers 12K FollowingOncologist, Professor, clinical/translational research, Genitourinary Cancers, bladder, prostate, testis, Univ of Washington, Fred Hutch; views are mine
7K Followers 2K FollowingDirector Division of Medical Oncology. Assoc Director Early Phase Clinical Trials The James Comprehensive Cancer Center. Prof. The OSU.Liquid Biopsy T/RT my own
4K Followers 307 FollowingCancer Researcher & Oncologist Prior @DanaFarber, Prof of Med @Harvardmed. Member @Uromigos. Dec 2022 Director @SAiGENCI and Prof at Uni of Adelaide. Views mine
29K Followers 865 FollowingEnte indipendente di ricerca e formazione che difende un servizio sanitario pubblico, equo e universalistico.
#SalviamoSSN #sostieniGIMBE
95 Followers 736 FollowingI am a Research Assistant, my interests are predictive and prognostic clinical and histopathologic markers for solid tumors, mainly Melanoma, NMSC and Sarcoma.